Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs

Does Allergen-specific Immunotherapy Induce Contact Allergy to Aluminium?

(2016) E Netterlid et al.   ACTA DERMATO-VENEREOLOGICA

Fluorescent nanodiamonds as a relevant tag for the assessment of alum adjuvant particle biodisposition

(2015) Housam Eidi et al.   BMC Medicine

Genetic basis of autoimmunity

(2015) Alexander Marson et al.   JOURNAL OF CLINICAL INVESTIGATION

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

(2015) Beatris Mastelic Gavillet et al.   JOURNAL OF IMMUNOLOGY

Cholera Toxin, and the Related Nontoxic Adjuvants mmCT and dmLT, Promote Human Th17 Responses via Cyclic AMP–Protein Kinase A and Inflammasome-Dependent IL-1 Signaling

(2015) Maximilian Larena et al.   JOURNAL OF IMMUNOLOGY

Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single–dose influenza vaccine protection

(2015) Yoshikazu Honda-Okubo et al.   VACCINE

A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection

(2015) Estela Rodriguez-Del Rio et al.   VACCINE

Aluminium in Allergies and Allergen immunotherapy

(2015) Erika Jensen-Jarolim   World Allergy Organization Journal

Advax-Adjuvanted Recombinant Protective Antigen Provides Protection against Inhalational Anthrax That Is Further Enhanced by Addition of Murabutide Adjuvant

(2014) Brandon Feinen et al.   Clinical and Vaccine Immunology

Phase I/II Randomized Double-Blind Study of the Safety and Immunogenicity of a Nonadjuvanted Vero Cell Culture-Derived Whole-Virus H9N2 Influenza Vaccine in Healthy Adults

(2014) Gerald Aichinger et al.   Clinical and Vaccine Immunology

Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts

(2014) Calvin C. Willhite et al.   CRITICAL REVIEWS IN TOXICOLOGY

Danger, diversity and priming in innate antiviral immunity

(2014) Susan E. Collins et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Hypersensitivity Reactions to Vaccine Constituents

(2014) Jonathan S. Leventhal et al.   Dermatitis

Shortcomings of pertussis vaccines: why we need a third generation vaccine

(2014) Jan T Poolman   Expert Review of Vaccines

Are there negative CNS impacts of aluminum adjuvants used in vaccines and immunotherapy?

(2014) Christopher A Shaw et al.   Immunotherapy

Th17 and Non-Classic Th1 Cells in Chronic Inflammatory Disorders: Two Sides of the Same Coin

(2014) Lorenzo Cosmi et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: What is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants

(2014) S. Sohail Ahmed et al.   JOURNAL OF AUTOIMMUNITY

Vaccination-Induced Systemic Autoimmunity in Farmed Atlantic Salmon

(2014) E. O. Koppang et al.   JOURNAL OF IMMUNOLOGY

Arthritis, a complex connective and synovial joint destructive autoimmune disease: Animal models of arthritis with varied etiopathology and their significance

(2014) SR Naik et al.   Journal of Postgraduate Medicine

Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology

(2014) Yoshikazu Honda-Okubo et al.   JOURNAL OF VIROLOGY

Assessment of benefits and risks in development of targeted therapies for cancer - The view of regulatory authorities

(2014) Francesco Pignatti et al.   Molecular Oncology

The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells

(2014) Joseph H. Lorent et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk

(2014) Outi Vaarala et al.   PLoS One

Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case–control study

(2014) A. Spadea et al.   VACCINE

Efficacy of ABX196, a new NKT agonist, in prophylactic human vaccination

(2014) Josianne Nitcheu Tefit et al.   VACCINE

Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: A randomized controlled Phase 1 study

(2014) David Gordon et al.   VACCINE

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

(2014) Julia Scheiermann et al.   VACCINE

Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere Trivalent Influenza Vaccine is associated with adverse events

(2014) Steve Rockman et al.   VACCINE

Aluminium in allergen-specific subcutaneous immunotherapy – A German perspective

(2014) Matthias F. Kramer et al.   VACCINE

A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection

(2014) Yoshikazu Honda-Okubo et al.   VACCINE

Ethical considerations in post-market-approval monitoring and regulation of vaccines

(2014) Alison Thompson et al.   VACCINE

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

(2014) Jaap T. van Dissel et al.   VACCINE

Aluminum exposure and toxicity in neonates: a practical guide to halt aluminum overload in the prenatal and perinatal periods

(2014) Daniela Fanni et al.   World Journal of Pediatrics

Intranasal Vaccination Promotes Detrimental Th17-Mediated Immunity against Influenza Infection

(2014) Asher Maroof et al.   PLoS Pathogens

Clinical Features in Patients with Long-Lasting Macrophagic Myofasciitis

(2014) Muriel Rigolet et al.   Frontiers in Neurology

Predictive markers of safety and immunogenicity of adjuvanted vaccines

(2013) Beatris Mastelic et al.   BIOLOGICALS

Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell death

(2013) Heriberto Lima Jr. et al.   CELL CYCLE

Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): clinical and immunological spectrum

(2013) Olga Vera-Lastra et al.   Expert Review of Clinical Immunology

Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity

(2013) C. A. Shaw et al.   IMMUNOLOGIC RESEARCH

Administration of aluminium to neonatal mice in vaccine-relevant amounts is associated with adverse long term neurological outcomes

(2013) C.A. Shaw et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Glucosamine Dose/Concentration-Effect Correlation in the Rat with Adjuvant Arthritis

(2013) Ali Aghazadeh-Habashi et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody

(2013) N. Petrovsky et al.   JOURNAL OF VIROLOGY

Treating inflammation by blocking interleukin-1 in humans

(2013) Charles A. Dinarello et al.   SEMINARS IN IMMUNOLOGY

A global regulatory science agenda for vaccines

(2013) Lindsay Elmgren et al.   VACCINE

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age

(2013) William L. Heyward et al.   VACCINE

Provider dismissal policies and clustering of vaccine-hesitant families

(2013) Alison M Buttenheim et al.   Human Vaccines & Immunotherapeutics

Rethinking vaccine policy making in an era of vaccine hesitancy: Time to rebuild, not remodel?

(2013) Douglas J Opel et al.   Human Vaccines & Immunotherapeutics

How society should respond to the risk of vaccine rejection

(2013) David Ropeik   Human Vaccines & Immunotherapeutics

Adjuvants for human vaccines

(2012) Carl R Alving et al.   CURRENT OPINION IN IMMUNOLOGY

Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine

(2012) Kae Pusic et al.   FASEB JOURNAL

Oily adjuvants and autoimmunity: now time for reconsideration?

(2012) M Whitehouse   LUPUS

Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld's syndrome)

(2012) O Vera-Lastra et al.   LUPUS

Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland

(2012) Markku Partinen et al.   PLoS One

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland

(2012) Hanna Nohynek et al.   PLoS One

Cell Recruitment and Cytokines in Skin Mice Sensitized with the Vaccine Adjuvants: Saponin, Incomplete Freund’s Adjuvant, and Monophosphoryl Lipid A

(2012) Juliana Vitoriano-Souza et al.   PLoS One

Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages

(2012) K. Schroder et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

(2012) Benjamin P. Sablan et al.   VACCINE

A genomics-based approach to assessment of vaccine safety and immunogenicity in children

(2012) Olivia J. White et al.   VACCINE

Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo

(2012) Marina Zaitseva et al.   VACCINE

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age

(2012) Scott A. Halperin et al.   VACCINE

Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant

(2012) David L. Gordon et al.   VACCINE

Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses

(2012) Yoshikazu Honda-Okubo et al.   VACCINE

Overview of global regulatory toxicology requirements for vaccines and adjuvants

(2012) Yuansheng Sun et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Carbohydrate-based immune adjuvants

(2011) Nikolai Petrovsky et al.   Expert Review of Vaccines

Induction of decreased fecundity by tetanus toxoid hyper-immunization in C57BL/6 mice depends on the applied adjuvant

(2011) Irena Živković et al.   Innate Immunity

Consent and public engagement in an era of expanded childhood immunisation

(2011) Julie Leask et al.   JOURNAL OF PAEDIATRICS AND CHILD HEALTH

A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720

(2011) James S. McCarthy et al.   PLoS One

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

(2011) Theodore F. Tsai et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Pandemic influenza A (H1N1) vaccination in The Netherlands: Parental reasoning underlying child vaccination choices

(2011) Marloes Bults et al.   VACCINE

Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults

(2011) Christine B. Turley et al.   VACCINE

Delta inulin: a novel, immunologically active, stable packing structure comprising  -D-[2 -> 1] poly(fructo-furanosyl)  -D-glucose polymers

(2010) P. D. Cooper et al.   GLYCOBIOLOGY

Heat-Labile Enterotoxins as Adjuvants or Anti-Inflammatory Agents

(2010) Shuang Liang et al.   IMMUNOLOGICAL INVESTIGATIONS

An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses

(2010) M. Lobigs et al.   JOURNAL OF GENERAL VIROLOGY

Flagellin as an Adjuvant: Cellular Mechanisms and Potential

(2010) S. B. Mizel et al.   JOURNAL OF IMMUNOLOGY

Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults

(2010) John J. Treanor et al.   VACCINE

AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity

(2009) A. M. Didierlaurent et al.   JOURNAL OF IMMUNOLOGY

How to win trust over flu

(2009)   NATURE

Regulators face tough flu-jab choices

(2009) Declan Butler   NATURE

Parental Refusal of Pertussis Vaccination Is Associated With an Increased Risk of Pertussis Infection in Children

(2009) J. M. Glanz et al.   PEDIATRICS

Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin

(2009) David J. M. Lewis et al.   PLoS One

Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants

(2009) Vishukumar Aimanianda et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Freeing vaccine adjuvants from dangerous immunological dogma

(2008) Nikolai Petrovsky   Expert Review of Vaccines

CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway

(2007) Wen Xu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY